Business
BullFrog AI Publishes Annual Letter to Shareholders
Highlights significant progress in 2025 and outlines commercial priorities and potential catalysts entering 2026GAITHERSBURG, Md., Dec. 30, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the release of its annual letter to shareholders, which highl
About this update from Bullfrog Ai Holdings, Inc.
[{"type":"image","alt":"BullFrog AI Holdings, Inc.","displaySize":"","headline":null,"caption":"BullFrog AI Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/40a6d1d7288dd7624185c5755b024c0e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cckXAhHY1jCBABonzk6CjQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/40a6d1d7288dd7624185c5755b024c0e","width":300,"height":73}},"lazy":false},{"type":"text","content":"Highlights significant progress in 2025 and outlines commercial priorities and potential catalysts entering 2026","length":112,"tagName":"p"},{"type":"text","content":"GAITHERSBURG, Md., Dec. 30, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the release of its annual letter to shareholders, which highlights progress made during 2025 and outlines key priorities and potential catalysts for the year ahead.","length":516,"tagName":"p"},{"type":"text","content":"Dear Fellow Shareholders,","length":25,"tagName":"p"},{"type":"text","content":"As we close 2025, I want to thank you for your continued support of BullFrog AI and to reflect on what has been a pivotal year for the Company. Over the past twelve months, we have made meaningful progress across technology development, commercial execution, and external validation—progress that we believe positions BullFrog AI for a transformative 2026.","length":356,"tagName":"p"},{"type":"text","content":"This year marked an important evolution for BullFrog AI, from platform development and early validation to commercialization and enterprise adoption. At the core of our approach is the belief that artificial intelligence should augment human expertise, not replace it, enabling scientists and clinicians to make better, faster, and more confident decisions across the drug discovery and development lifecycle through causal, explainable AI. In 2025, this philosophy guided the foundational progress we made in strengthening our technology, validating its real-world relevance, and positioning the...